
CNS Pharmaceuticals CNSP
$ 4.44
6.22%
Country |
|
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
443 K |
Market Cap[1] |
$ 1.97 M |
EBITDA (LTM) |
$ -16.3 M |
P/E (LTM) |
-0.18539 |
P/S (LTM) |
- |
EPS (LTM) |
-18.07 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Shattuck Labs
STTK
|
$ 4.48 | -2.4 % | $ 312 M | Nasdaq Global Select Market | ||
|
Silence Therapeutics plc
SLN
|
$ 19.82 | 0.08 % | $ 2.81 B | Nasdaq Global Select Market | ||
|
Soligenix
SNGX
|
$ 0.25 | -10.34 % | $ 1.3 M | Nasdaq Capital Market | ||
|
Sanofi
SNY
|
$ 47.19 | -0.73 % | $ 57.6 B | Nasdaq Global Select Market | ||
|
Spruce Biosciences
SPRB
|
$ 40.66 | 0.42 % | $ 31.2 M | Nasdaq Global Select Market | ||
|
Spero Therapeutics
SPRO
|
$ 0.87 | -3.47 % | $ 48.7 M | Nasdaq Global Select Market | ||
|
Sarepta Therapeutics
SRPT
|
$ 14.54 | -1.56 % | $ 1.46 B | Nasdaq Global Select Market,SPB | ||
|
Savara
SVRA
|
$ 4.7 | 4.8 % | $ 1.05 B | Nasdaq Global Select Market | ||
|
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | ||
|
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | ||
|
Sutro Biopharma
STRO
|
$ 8.47 | -5.04 % | $ 72 M | Nasdaq Global Select Market | ||
|
Tarsus Pharmaceuticals
TARS
|
$ 75.97 | -2.85 % | $ 3.17 B | Nasdaq Global Select Market | ||
|
Supernus Pharmaceuticals
SUPN
|
$ 36.28 | 1.88 % | $ 2.05 B | Nasdaq Global Select Market,SPB | ||
|
TG Therapeutics
TGTX
|
$ 66.13 | 5.45 % | $ 9.54 B | Nasdaq Capital Market | ||
|
Aphria Inc.
APHA
|
- | -0.45 % | $ 4.87 B | Nasdaq Global Select Market | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
- | -0.90 % | $ 104 M | Nasdaq Capital Market | ||
|
Chiasma, Inc.
CHMA
|
- | -6.00 % | $ 238 M | Nasdaq Global Select Market | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
- | - | $ 376 M | Nasdaq Global Market | ||
|
Cellect Biotechnology Ltd.
APOP
|
- | 0.38 % | $ 12.9 M | Nasdaq Global Select Market | ||
|
AzurRx BioPharma, Inc.
AZRX
|
- | 2.07 % | $ 34.4 M | Nasdaq Capital Market | ||
|
Cerecor Inc.
CERC
|
- | -1.68 % | $ 283 M | Nasdaq Capital Market | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
- | - | $ 1.63 B | Nasdaq Global Select Market | ||
|
Auris Medical Holding Ltd.
EARS
|
- | -1.77 % | $ 39.2 M | Nasdaq Capital Market | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
- | 0.34 % | $ 2.98 B | Nasdaq Global Select Market,SPB | ||
|
ERYTECH Pharma S.A.
ERYP
|
- | 1.3 % | $ 27.7 M | Nasdaq Global Select Market | ||
|
GW Pharmaceuticals plc
GWPH
|
- | - | $ 6.81 B | Nasdaq Global Select Market | ||
|
Kadmon Holdings, Inc.
KDMN
|
- | - | $ 1.7 B | Nasdaq Global Select Market | ||
|
Liminal BioSciences
LMNL
|
- | - | $ 256 M | Nasdaq Global Market | ||
|
argenx SE
ARGX
|
$ 940.88 | -0.7 % | $ 57.7 B | Nasdaq Global Select Market | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 2.86 | -4.25 % | $ 24.3 M | Nasdaq Global Select Market | ||
|
Neos Therapeutics, Inc.
NEOS
|
- | -2.54 % | $ 57.2 M | Nasdaq Global Market | ||
|
Xenetic Biosciences
XBIO
|
$ 1.52 | -5.59 % | $ 2.59 M | Nasdaq Capital Market | ||
|
Odonate Therapeutics, Inc.
ODT
|
- | -3.18 % | $ 58.5 M | Nasdaq Global Select Market | ||
|
Orphazyme A/S
ORPH
|
- | -2.25 % | $ 31.3 M | Nasdaq Global Select Market | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
- | -10.74 % | $ 89.9 M | Nasdaq Global Select Market | ||
|
Pandion Therapeutics, Inc.
PAND
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
Xenon Pharmaceuticals
XENE
|
$ 37.93 | -2.19 % | $ 3.01 B | Nasdaq Global Select Market | ||
|
Xeris Pharmaceuticals
XERS
|
$ 16.95 | 0.92 % | $ 2.72 B | Nasdaq Global Select Market | ||
|
22nd Century Group
XXII
|
$ 0.38 | -14.05 % | $ 69.9 K | NYSE American | ||
|
Translate Bio, Inc.
TBIO
|
- | - | $ 2.81 B | Nasdaq Global Select Market,SPB | ||
|
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | ||
|
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market | ||
|
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | ||
|
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market | ||
|
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | ||
|
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
- | -7.58 % | $ 264 M | Nasdaq Global Select Market | ||
|
Taysha Gene Therapies
TSHA
|
$ 3.99 | -0.25 % | $ 1.28 B | Nasdaq Global Select Market | ||
|
Zentalis Pharmaceuticals
ZNTL
|
$ 1.38 | -7.38 % | $ 99.2 M | Nasdaq Global Market | ||
|
Zoetis
ZTS
|
$ 85.52 | 2.44 % | $ 37.9 B | NYSE,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.